Idiopathic triglyceride deposit cardiomyovasculopathy
Conditions
Interventions
Study drug: CNT-01 500 mg, 1500 mg or 4500 mg is administered orally as a single dose or three times daily for 7 days.
Control drug: CNT-01 placebo is administered orally as a single dose or three tim
Sponsors
Akita Yasuhiko
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Subjects who signed the written informed consent 2) Age>=20 and ==45kg, height>=140 cm, and body mass index (BMI) >=18.5 and <25.0 at screening
Exclusion criteria
Exclusion criteria: 1) Subjects with complications such as medically significant gastrointestinal, renal, respiratory, endocrine, hematological, nervous, psychiatric, cardiovascular, or congenital metabolic abnormalities. 2) Subjects with acute illness within 2 weeks prior to administration of the investigational drug. 3) Subjects with a current or past history of drug or food allergy. 4) Subjects with QTcF of 450 msec or more, PR interval of 220 msec or more, or QRS width of 120 msec or more on 12-lead ECG performed before administration on Day 1. 5) Subjects with a history of syncope. 6) Subjects with family history of congenital long QT syndrome or sudden cardiac death. 7) Patients with a history of infection requiring treatment within 4 weeks prior to administration of the investigational drug. 8) Persons with a positive SARS-CoV-2 test (nucleic acid amplification test) or suspected COVID-19 test performed within 3 days before admission to the hospital.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics, Effect on QTcF and Safety | — |
Contacts
Public ContactClinical Development Dept.
TOA EIYO LTD.
Outcome results
None listed